



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

26th July 2023

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q1 of 2023-24

Please find enclosed a press release issued by the Company in respect of financial results for the quarter ended 30th June 2023.

This is for your information and record.

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151



Press release

For media and investors only

General Medicines delivers 4% revenue growth despite NLEM impact along with a sequential recovery in the vaccines business

July 26, Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK) today declared its financial results for quarter ended June 30, 2023. Revenue from operations for the quarter grew by ~ 1% at INR 738 crores. The company maintained its gross margins despite the NLEM impact, while EBITDA margins declined ~ 1% on account of new product launch investments led by Shingrix. Profit After Tax (PAT) for the quarter at INR 131 crores grew by ~ 13%.

During the quarter, the company delivered a robust volume growth of 8% for its key promoted portfolio with market share gains. This along with the implementation of WPI price increases, has helped offset the NLEM impact. In addition, GSK's vaccines business has now demonstrated a sequential Q-o-Q increase and maintained leadership in the private self-pay market.

Aligned with our purpose of providing access to our innovative portfolio, GSK successfully launched Shingrix, a vaccine for the prevention of Herpes Zoster (shingles) and Post-herpetic neuralgia in adults aged 50 years and above, marking the company's entry in this important adult immunisation category.

Mr. Bhushan Akshikar, Managing Director, GSK Pharmaceuticals Limited, said, "Despite the strong external headwinds, GSK remains focused on delivering best-in-class competitive performance and driving operational efficiencies. We remain committed to explore new growth opportunities and improving our leadership in key therapy areas."

About GlaxoSmithKline Pharmaceuticals Limited (GSK):

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, a science-led global healthcare company with a purpose to unite science, technology and talent to get ahead of disease together. For more information, visit GSK-India.com

Media Contact:

Ransom D' Souza – ransom.a.dsouza@gsk.com

Communications & Government Affairs